OncoMatch/Endometrial / Uterine Cancer/PD-L1 (CD274)
Endometrial / Uterine CancerPD-L1 (CD274) Clinical Trials
PD-L1 expression guides pembrolizumab monotherapy eligibility in previously treated endometrial cancer (CPS ≥10 per KEYNOTE-158); the pembrolizumab plus lenvatinib combination is approved regardless of PD-L1 level. Higher PD-L1 CPS correlates with greater monotherapy benefit in MMR-proficient tumors. Trials evaluate novel checkpoint combinations, LAG-3/TIGIT inhibitors, and neoadjuvant IO in PD-L1-stratified endometrial cancer.
Top recruiting PD-L1 (CD274) Endometrial / Uterine Cancer trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Browse other molecular targets with active Endometrial / Uterine Cancer trials.